13. Meyer HM, et al. Response of Volta children to jet inoculation of combined live measles, smallpox, and yellow fever vaccines. Bull World Health Org 1964;30:783-794.

14. Bancroft WH, et al. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 1984;149:1005-1010.

15. Jackson J, et al. Comparison of Antibody Response and Patient Tolerance of Yellow Fever Vaccine Administered by the Bioject Needle-Free Injection System versus Conventional Needle/Syringe Injection. Third International Conference on Travel Medicine; Paris 1993;April:25-29;264:209.

16. Monath TP, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a Phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66(5)2002;533-541.

17. Goujon C, et al. Good Tolerance and Efficacy of Yellow Fever Vaccine Among Subjects Carriers of Human Immunodeficiency Virus. Fourth International Conference on Travel Medicine; Acapulco, Mexico 1995;April:23-27;32:63.

18. Nasidi A, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Transactions of the Royal Society of Tropical Medicine and Hygiene 1993;87:337-339.

19. Bonnevie-Nielson V, et al. Lymphocytic 2', 5'— Oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and Immunoglobulin M and Immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diag Lab Immunol 1995;2:302-306.

20. Smithburn KC, et al. Immunization against yellow fever: Studies on the time of development and the duration of induced immunity. Am J Trop Med Hyg 1945;45:217-223.

21. World Health Organization (WHO). International Health Regulations (1969) (3^rd annotated edition). Geneva 1983:30-65.

Bookmark this page: